Hengrui Pharmaceutical announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” for injectable ricaximab from the State Drug Administration and agreed to conduct phase III clinical trials. The indications are for adult patients with intracranial atherosclerotic stenosis to reduce the risk of recurrence of stroke.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.